BRIEF published on 01/22/2026 at 15:00, 3 hours 55 minutes ago Sparton Resources Inc. Secures Approval for Private Placement Private Placement Regulatory Approval Flow-through Shares Resource Exploration Sparton Resources
BRIEF published on 01/22/2026 at 15:00, 3 hours 55 minutes ago Sparton Resources Inc. obtient l'approbation pour un placement privé Placement Privé Actions Accréditives Exploration Des Ressources Approbation Réglementaire Ressources Sparton
PRESS RELEASE published on 01/22/2026 at 14:55, 4 hours ago Sparton Resources Inc. Final Approval for Private Placement and Updates Sparton Resources Inc. receives final approval for C$410,000 private placement offering for resource exploration. Proceeds to fund Critical Metals projects in Ontario and Quebec Private Placement Resource Exploration Critical Metals Projects Sparton Resources Inc. Ontario And Quebec
Published on 01/22/2026 at 18:37, 18 minutes ago Kootenay Silver Announces Upsize of Bought Deal LIFE Private Placement to Gross Proceeds of C$16.5 Million
Published on 01/22/2026 at 15:50, 3 hours 5 minutes ago Premier American Uranium Announces Upsize of Bought Deal Private Placement to C$13 Million
Published on 01/22/2026 at 15:00, 3 hours 55 minutes ago Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
Published on 01/22/2026 at 14:55, 4 hours ago Sparton Resources Inc. Final Approval for Private Placement and Updates
Published on 01/22/2026 at 18:37, 17 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/22/2026 at 18:24, 30 minutes ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 01/22/2026 at 18:21, 33 minutes ago Turkiye Garanti Bankasi A.S.: Redemption of the debt instrument at abroad within the Medium Term Note (MTN) program
Published on 01/22/2026 at 18:00, 55 minutes ago BIOSYNEX SA: CHEMBIO DIAGNOSTIC SYSTEMS INC., FILIALE DE BIOSYNEX, ANNONCE LE DOUBLE DÉPÔT À LA FDA DU TEST DPP® SYPHILIS TnT SUITE À LA DÉSIGNATION DE DISPOSITIF INNOVANT (BREAKTHROUGH DEVICE)
